Höfflin R, Roth W, Sültmann H, Grüllich C, Hatiboglu G, Nyarangi-Dix J, Schönberg G, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S
Sektion Molekulare Uroonkologie, Urologische Universitätsklinik, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 517, 69120, Heidelberg, Deutschland.
Urologe A. 2015 Jun;54(6):800-3. doi: 10.1007/s00120-015-3800-9.
Advanced clear cell renal cell carcinoma is characterized by extensive intratumoral genomic heterogeneity and branched as well as convergent evolutionary traits with genomically different subclones evolving in parallel in the same tumor. Distinct driver mutations can be found in spatially separated subclones, which may hinder the development of novel targeted therapies. However, truncal mutations of the VHL tumor suppressor gene and chromosome 3p loss were ubiquitously detected and will hence continue to be a focus of future drug development. Nevertheless, genomic instability, enhanced tumor genome plasticity and intratumoral heterogeneity are likely to represent major challenges towards biomarker development and personalized patient care.
晚期透明细胞肾细胞癌的特征是肿瘤内存在广泛的基因组异质性,具有分支和趋同的进化特征,基因组不同的亚克隆在同一肿瘤中平行进化。在空间上分离的亚克隆中可发现不同的驱动突变,这可能会阻碍新型靶向治疗的开发。然而,普遍检测到VHL肿瘤抑制基因的截短突变和3号染色体缺失,因此它们仍将是未来药物开发的重点。尽管如此,基因组不稳定性、增强的肿瘤基因组可塑性和肿瘤内异质性可能是生物标志物开发和个性化患者护理面临的主要挑战。